Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for... see more

Recent & Breaking News (NYSE:MRK)

Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma

Business Wire December 18, 2013

Heat Biologics, Inc. Appoints Dr. Anil K. Goyal as Vice President of Business Development

Marketwired December 17, 2013

Merck Statement on FDA Advisory Committee for GRASTEK® (Timothy Grass Pollen Allergen Extract), Merck's Investigational Sublingual Allergy Immunotherapy Tablet

Business Wire December 12, 2013

Merck Advances Development Program for Investigational Alzheimer's Disease Therapy, MK-8931

Business Wire December 10, 2013

Merck Announces Increased Quarterly Dividend

Business Wire November 26, 2013

FDA Approves Merck's NOXAFIL® (posaconazole) Delayed-Release Tablets

Business Wire November 26, 2013

Merck for Mothers Working to End the Tragedy of Women in America Dying in Childbirth and Pregnancy

PR Newswire November 19, 2013

Additional Interim Data for Merck's Investigational Anti-PD-1 Immunotherapy, MK-3475, Shows Estimated Overall Survival Rate of 81 Percent at One Year in Patients with Advanced Melanoma

Business Wire November 18, 2013

Interim Data to Be Presented for MK-3475, Merck's Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma

Business Wire November 15, 2013

Merck's Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study

Business Wire November 9, 2013

Merck's Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study

Business Wire November 4, 2013

Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Business Wire November 2, 2013

Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Canada NewsWire November 2, 2013

Five Star Equities Issues New Research Reports on DNDN, EW, MRK and ZGNX

Accesswire October 31, 2013

Merck Announces Presentation of Interim Data from Phase 1B Study of MK-3475, Investigational anti-PD-1 Immunotherapy, in Previously-Treated Patients with Non-Small Cell Lung Cancer (NSCLC) at 15th World Conference on Lung Cancer

Business Wire October 29, 2013

NQ, FIO, MRK and PBR added to NYSE Active Stock Watch List at GSR

Accesswire October 28, 2013

Merck Announces Third-Quarter 2013 Financial Results

Business Wire October 28, 2013

Merck Provides Update on Investigational 9-valent HPV Vaccine V503 to U.S. Advisory Committee on Immunization Practices

Business Wire October 24, 2013

ZOSTAVAX® (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product

Business Wire October 23, 2013

Merck Receives Breakthrough Therapy Designation for MK-5172/MK-8742, an Investigational Oral Combination Regimen for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Business Wire October 22, 2013